Causal therapy of diseases or conditions associated with cns or pns demyelination

A method of causal treatment or prevention of a disease or condition associated with central nervous system (CNS) or peripheral nervous system (PNS) demyelination in a mammal, the method comprising maintaining the integrity of myelination of axonal cells by administering to the mammal a 2-oxopyrrolidine compound having a general formula I:

• wherein R is hydrogen, hydroxyl or aminomethyl;
• R′ is hydrogen or piperidinocarbonyl group;
• R″ is hydrogen, aminocarbonylalkyl optionally N-substituted with a di(C1-C4)alkylamino-(C2-C4)alkyl group, anilinocarbonylalky optionally mono or disubstituted on the benzene ring with methyl, methoxy, or halogen;
• benzyl, optionally mono or disubstituted on the benzene ring with methyl, methoxy, or halogen;
• wherein one or two of R, R′ and R″ is hydrogen;
• with the provisos that when R′ is other than hydrogen, then R and R″ are both hydrogen, and when R is other then hydrogen, then R′ is hydrogen, or a pharmaceutically acceptable salt thereof.

A method of treatment or prevention of a disease or condition associated with central nervous system (CNS) or peripheral nervous system (PNS) demyelination in a mammal, the method comprising maintaining the integrity of myelination of axonal cells by administering an immune mediated therapeutic and a 2-oxopyrrolidine compound having a general formula I:

• wherein R is hydrogen, hydroxyl or aminomethyl;
• R′ is hydrogen or piperidinocarbonyl group;
• R″ is hydrogen, aminocarbonylalkyl optionally N-substituted with a di(C1-C4)alkylamino-(C2-C4)alkyl group, anilinocarbonylalky optionally mono or disubstituted on the benzene ring with methyl, methoxy, or halogen;
• benzyl, optionally mono or disubstituted on the benzene ring with methyl, methoxy, or halogen;
• wherein one or two of R, R′ and R″ is hydrogen;
• with the provisos that when R′ is other than hydrogen, then R and R″ are both hydrogen, and when
• R is other then hydrogen, then R′ is hydrogen, or a pharmaceutically acceptable salt thereof.

A method for the treatment of one or more symptoms of a disease or condition associated with CNS or PNS demyelination in a human subject, in which the symptoms are selected from a group consisting of vision deficits, motor control deficits, sensation deficits, the method comprising the steps of administering to the subject an amount of a 2-oxypyrollidone compound effective to cause a clinically significant remyelination of CNS or PNS neuronal cells, wherein the 2-oxopyrrolidine compound has a general formula I:

• wherein R is hydrogen, hydroxyl or aminomethyl;
• R′ is hydrogen or piperidinocarbonyl group;
• R″ is hydrogen, aminocarbonylalkyl optionally N-substituted with a di(C1-C4)alkylamino-(C2-C4)alkyl group, anilinocarbonylalky optionally mono or disubstituted on the benzene ring with methyl, methoxy, or halogen;
• benzyl, optionally mono or disubstituted on the benzene ring with methyl, methoxy, or halogen;
• wherein one or two of R, R′ and R″ is hydrogen;
• with the provisos that when R′ is other than hydrogen, then R and R″ are both hydrogen, and when R is other then hydrogen, then R′ is hydrogen, or a pharmaceutically acceptable salt thereof.

A pharmaceutical composition comprising a 2-oxopyrrolidine compound and an immune mediated therapeutic, in combination with a suitable pharmaceutical carrier or diluent, wherein the 2-oxopyrrolidine compound has a general formula I:

• wherein R is hydrogen, hydroxyl or aminomethyl;
• R′ is hydrogen or piperidinocarbonyl group;
• R″ is hydrogen, aminocarbonylalkyl optionally N-substituted with a di(C1-C4)alkylamino-(C2-C4)alkyl group, anilinocarbonylalky optionally mono or disubstituted on the benzene ring with methyl, methoxy, or halogen;
• benzyl, optionally mono or disubstituted on the benzene ring with methyl, methoxy, or halogen;
• wherein one or two of R, R′ and R″ is hydrogen;
• with the provisos that when R′ is other than hydrogen, then R and R″ are both hydrogen, and when R is other then hydrogen, then R′ is hydrogen, or a pharmaceutically acceptable salt thereof.